Close
  • Home

CAR-T Digest - August 2020

CAR-T Digest - August 2020

CAR-T Digest - August 2020

CAR-T Digest - August 2020

Funding

Approval  ·  Weekly Digest - 23 May to 29 May 2026
U.S. FDA approves DECNUPAZ for adult patients with BPDCN, a rare aggressive Blood cancer

Weekly Digest – May 2026 Weekly Digest – May 2026 27 May 2026: U.S. FDA approves DECNUPAZ for adult patients with BPDCN, a rare aggressive Blood cancer AbbVie has secured U.S. FDA approval for DECNUPAZ in blastic plasmacytoid dendritic cell […]

by Sandhya Ramalingam

Continue Reading
Approval  ·  Weekly Digest - 23 May to 29 May 2026
Datroway approved in the U.S. as first TROP2-directed ADC for 1L metastatic TNBC patients ineligible for PD-1/PD-L1 inhibitors

Weekly Digest – May 2026 Weekly Digest – May 2026 22 May 2026: Datroway approved in the U.S. as first TROP2-directed ADC for 1L metastatic TNBC patients ineligible for PD-1/PD-L1 inhibitors AstraZeneca and Daiichi Sankyo have secured U.S. FDA approval […]

by Sandhya Ramalingam

Continue Reading
Regulatory  ·  Weekly Digest - 23 May to 29 May 2026
CHMP recommends EU approval of Enhertu for previously treated HER2-positive metastatic Solid tumours

Weekly Digest – May 2026 Weekly Digest – May 2026 22 May 2026: CHMP recommends EU approval of Enhertu for previously treated HER2-positive metastatic Solid tumours AstraZeneca and Daiichi Sankyo have received a positive CHMP opinion for Enhertu in previously […]

by Sandhya Ramalingam

Continue Reading
Regulatory  ·  Weekly Digest - 23 May to 29 May 2026
Gilead receives CHMP positive opinion for Trodelvy in 1L metastatic TNBC patients ineligible for PD-(L)1 inhibitors

Weekly Digest – May 2026 Weekly Digest – May 2026 22 May 2026: Gilead receives CHMP positive opinion for Trodelvy in 1L metastatic TNBC patients ineligible for PD-(L)1 inhibitors Gilead has received a positive CHMP opinion for Trodelvy in the […]

by Sandhya Ramalingam

Continue Reading
Regulatory  ·  Weekly Digest - 23 May to 29 May 2026
Sino Biopharmaceuticals CLDN18.2 ADC LM-302 granted Priority Review with China approval expected

Weekly Digest – May 2026 Weekly Digest – May 2026 25 May 2026: Sino Biopharmaceuticals CLDN18.2 ADC LM-302 granted Priority Review with China approval expected Sino Biopharmaceuticals CLDN18.2-targeted ADC LM-302 has entered China’s priority review pathway, positioning the asset for […]

by Sandhya Ramalingam

Continue Reading
Deals  ·  Weekly Digest - 23 May to 29 May 2026
Adcendo and MSD partner to evaluate ADCE-T02 plus KEYTRUDA in phase 1b advanced Solid tumor study

Weekly Digest – May 2026 Weekly Digest – May 2026 26 May 2026: Adcendo and MSD partner to evaluate ADCE-T02 plus KEYTRUDA in phase 1b advanced Solid tumor study Adcendo has entered a clinical collaboration and supply agreement with MSD […]

by Sandhya Ramalingam

Continue Reading
Approval  ·  Weekly Digest - 16 May to 22 May 2026
ENHERTU approved in the US for two new indications for patients with HER2-positive early Breast cancer

Weekly Digest – May 2026 Weekly Digest – May 2026 15 May 2026: ENHERTU approved in the US for two new indications for patients with HER2-positive early Breast cancer ENHERTU received two new U.S. FDA approvals in HER2-positive early breast […]

by Sandhya Ramalingam

Continue Reading
Approval  ·  Weekly Digest - 16 May to 22 May 2026
CDSCO approves Astellas’ PADCEV for first-line advanced Bladder cancer treatment

Weekly Digest – May 2026 Weekly Digest – May 2026 21 May 2026: CDSCO approves Astellas’ PADCEV for first-line advanced Bladder cancer treatment Astellas Pharma’s PADCEV has been approved by CDSCO for first-line treatment of locally advanced or metastatic urothelial […]

by Sandhya Ramalingam

Continue Reading
Regulatory  ·  Weekly Digest - 16 May to 22 May 2026
PADCEV in combination with Keytruda receives positive CHMP opinion for the treatment of patients with resectable MIBC who are ineligible for cisplatin-based chemotherapy

Weekly Digest – May 2026 Weekly Digest – May 2026 22 May 2026: PADCEV in combination with Keytruda receives positive CHMP opinion for the treatment of patients with resectable MIBC who are ineligible for cisplatin-based chemotherapy Astellas Pharma announced that […]

by Sandhya Ramalingam

Continue Reading
Clinical  ·  Weekly Digest - 16 May to 22 May 2026
TroFuse-005 trial evaluating Sacituzumab Tirumotecan met primary endpoints of OS and PFS in certain patients with advanced or recurrent Endometrial cancer

Weekly Digest – May 2026 Weekly Digest – May 2026 18 May 2026: TroFuse-005 trial evaluating Sacituzumab Tirumotecan met primary endpoints of OS and PFS in certain patients with advanced or recurrent Endometrial cancer Merck & Co. announced that the […]

by Sandhya Ramalingam

Continue Reading
‹ Previous12345678Next ›Last »
Page 4 of 50


Contact:

  info@ciscientists.com

 +1-908-212-7484

Optimal Dose

For a subscription, please provide your email id